TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30035423

Group type: EXPERIMENTAL
Intervention: Speroton complex with general therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: General therapy (Control Group)
Number of subjects: 60
Study: 27484782

Group type: EXPERIMENTAL
Intervention: LED-RL phototherapy at doses of 160 J/cm², 320 J/cm², 480 J/cm², and 640 J/cm²
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mock therapy
Number of subjects: 50
Study: 25236915

Group type: EXPERIMENTAL
Intervention: Vilazodone (5 mg) with ketoconazole (200 mg once daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vilazodone (10 mg) with ketoconazole (200 mg once daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vilazodone (40 mg once daily) with carbamazepine (steady-state)
Number of subjects: 67
Study: 22745661

Group type: EXPERIMENTAL
Intervention: Atrial lead with a tip-to-ring spacing of 1.1 mm, programmed with postventricular atrial blanking (PVAB) to 60 ms
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional atrial lead with a tip-to-ring spacing of 10 mm, programmed with individually determined optimized PVAB
Number of subjects: 204
Study: 19995884

Group type: EXPERIMENTAL
Intervention: Restriction of time in bed by delaying bedtime 30 minutes nightly for 18 months, together with education in healthy sleep practices (SLEEP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Attention‐only control condition with education in health dietary practices (NUTRITION)
Number of subjects: 64
Study: 18277515

Group type: EXPERIMENTAL
Intervention: Small images (less than 10 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large images (10 degrees or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated image generation over 3 consecutive blocks
Number of subjects: 0
Study: 15206537

Group type: EXPERIMENTAL
Intervention: Active treatment with bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11353457

Group type: EXPERIMENTAL
Intervention: Cardiac Home Information Program (CHIP) plus usual care
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual cardiac discharge information protocol
Number of subjects: 180
Study: 9389897

Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (Mg(OH)2; 411-548 mg Mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8198658

Group type: EXPERIMENTAL
Intervention: 1 g intravenous loading dose of phenytoin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 500 mg oral phenytoin supplementation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 g intravenous loading dose of phenytoin (entire group analysis)
Number of subjects: 28
Study: 3370401

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29467025

Group type: EXPERIMENTAL
Intervention: Individualized BP lowering (10‐15% reduction from admission level)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Guideline‐recommended BP lowering
Number of subjects: 500
Study: 27542303

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 μg/kg per h, from ICU admission on the day of surgery until 0800 h on postoperative day 1)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo (intravenous normal saline)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 μg/kg per h)
Number of subjects: 700
Study: 25690266

Group type: EXPERIMENTAL
Intervention: GP-led telephone triage (GPT)
Number of subjects: 20990

Group type: EXPERIMENTAL
Intervention: Nurse-led computer-supported telephone triage (NT)
Number of subjects: 20990

Group type: COMPARATOR
Intervention: Overall costs
Number of subjects: 20990

Group type: COMPARATOR
Intervention: Triage (GPT and NT)
Number of subjects: 20990
Study: 24139151

Group type: EXPERIMENTAL
Intervention: Single stretching group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Eccentric exercise group followed by a single bout of stretching
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Eccentric exercise group submitted to repeated bouts of stretching
Number of subjects: 56

Group type: COMPARATOR
Intervention: Eccentric exercised group
Number of subjects: 56
Study: 21068687

Group type: EXPERIMENTAL
Intervention: 4-week youth baseball conditioning program (3 sessions per week, 75 minutes each)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 18715160

Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPV23 booster 8 weeks later (primed group)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo followed by standard single dose of PPV23 (unprimed group)
Number of subjects: 130
Study: 16377322

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg intravenously
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 12679174

Group type: EXPERIMENTAL
Intervention: 2 g/d plant stanol (3.4 g of stanol ester)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 3 g/d plant stanol (5.1 g of stanol ester)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 105
Study: 11122545

Group type: EXPERIMENTAL
Intervention: Early triage angiography and subsequent therapies based on the angiogram
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 201
Study: 9169300

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 +/- 2.5 mg/day, 10 +/- 2.5 mg/day, 15 +/- 2.5 mg/day)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Haloperidol (15 +/- 5 mg/day)
Number of subjects: 431
Study: 1383071

Group type: EXPERIMENTAL
Intervention: rIFN-alpha therapy
Number of subjects: 122
Study: 6092305

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Naloxone vehicle (control)
Number of subjects: 12
Study: 31390464

Group type: EXPERIMENTAL
Intervention: AF-Clinic (integrated chronic care programme)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Usual care by a cardiologist
Number of subjects: 712
Study: 29532078

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Teen‐LABS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Medical therapy (TODAY)
Number of subjects: 93
Study: 27002003

Group type: EXPERIMENTAL
Intervention: Morphine Group (10 mg bupivacaine 0.5% and 0.5 mg morphine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine-Dex Group (10 mg bupivacaine 0.5%, 0.5 mg morphine and 5 µg dexmedetomidine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine Group (10 mg bupivacaine 0.5%)
Number of subjects: 90
Study: 25298196

Group type: EXPERIMENTAL
Intervention: Referral to group therapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Referral to individual web-based tobacco treatment
Number of subjects: 272
Study: 22252038

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SN) mapping with immunohistochemical analysis
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard nodal staging
Number of subjects: 331
Study: 20357370

Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/day for younger girls and 850 mg/day for older girls)
Number of subjects: 85
Study: 19338489

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1 g twice daily) in combination with cyclosporine and steroids (impaired group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (normal graft function)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Correlation with glomerular filtration rate
Number of subjects: 26
Study: 15793608

Group type: EXPERIMENTAL
Intervention: Aggressive LDL-C lowering (high-dose lovastatin therapy)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Moderate LDL-C lowering (low-dose lovastatin therapy)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Abnormally high BMI (BMI > or = 25 kg/m2)
Number of subjects: 145
Study: 11875999

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 194
Study: 10088567

Group type: EXPERIMENTAL
Intervention: Intravenous insulin at 0.043 U/kg per hour
Number of subjects: 10

Group type: COMPARATOR
Intervention: No intravenous insulin administration
Number of subjects: 10
Study: 7738484

Group type: EXPERIMENTAL
Intervention: Smokers (abstinent from tobacco for 48 h or allowed to smoke freely)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 22
Study: 1823632

Group type: EXPERIMENTAL
Intervention: Melatonin therapy (5 mg/m2/day to 700 mg/m2/day in four divided doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Melatonin therapy
Number of subjects: 40
Study: 6367857

Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone) for 1 year
Number of subjects: 358

Group type: COMPARATOR
Intervention: L-PAM (L-phenylalanine mustard) for 2 years
Number of subjects: 358
Study: 30514653

Group type: EXPERIMENTAL
Intervention: Estradiol (females)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: DHEA (males)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Testosterone (males)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: DHEA (females)
Number of subjects: 165
Study: 30347031

Group type: EXPERIMENTAL
Intervention: Early ECMO
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional lung-protective ventilation
Number of subjects: 249
Study: 27075913

Group type: EXPERIMENTAL
Intervention: Folic Acid 600 μg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24560401

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1005

Group type: COMPARATOR
Intervention: ANGIO (angiography guidance)
Number of subjects: 1005
Study: 22591408

Group type: EXPERIMENTAL
Intervention: Neurosurgical treatment for SAH
Number of subjects: 178
Study: 20349685

Group type: EXPERIMENTAL
Intervention: Sertaconazole nitrate cream 2%
Number of subjects: 92
Study: 16900567

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16452557

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose levels normalized to 80 to 110 mg/dL using insulin infusion)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (for patients staying in ICU for three or more days)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Conventional therapy (insulin administered when blood glucose exceeded 215 mg/dL)
Number of subjects: 1200
Study: 14998225

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study: 11232529

Group type: COMPARATOR
Intervention: Capozide-50 (C-50) alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Capozide-50 (C-50) + melatonin (3 mg at 10.00 p.m.)
Number of subjects: 22
Study: 8737131

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg
Number of subjects: 238

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 238
Study: 1572085

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN-gamma)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 4064778

Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Porcine heparin
Number of subjects: 104
Study: 31350248

Group type: EXPERIMENTAL
Intervention: STUMBL score (prognostic model)
Number of subjects: 176
Study: 29234750

Group type: COMPARATOR
Intervention: Intraoral radiography
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vertical probing distance (VPD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bone sounding without flap elevation
Number of subjects: 23
Study: 25549210

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134
Study: 24321569

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric plication (LGP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic mini-gastric bypass (LMGB)
Number of subjects: 40
Study: 21668799

Group type: COMPARATOR
Intervention: Clear fluids at room temperature, 2 h after emergence (C1)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Clear fluids at body temperature, 2 h after emergence (C2)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Clear fluids at room temperature, 1 h after emergence (E1)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Clear fluids at body temperature, 1 h after emergence (E2)
Number of subjects: 237
Study: 18093254

Group type: EXPERIMENTAL
Intervention: 25 mg kg(‐1) pyrazinamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: 15 mg kg(‐1) pyrazinamide
Number of subjects: 20
Study: 16782182

Group type: EXPERIMENTAL
Intervention: Enhanced guideline implementation (clinic-level intervention)
Number of subjects: 3509

Group type: EXPERIMENTAL
Intervention: Chart prompt intervention
Number of subjects: 3509

Group type: COMPARATOR
Intervention: Standard guideline implementation (control)
Number of subjects: 3509
Study: 12589392

Group type: EXPERIMENTAL
Intervention: Delta(9)-THC (up to 10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10952732

Group type: EXPERIMENTAL
Intervention: Congenitally deaf individuals
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normally hearing individuals
Number of subjects: 2
Study: 8615355

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (400 IU, n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: all-rac-alpha-tocopheryl acetate (400 mg, n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: water-miscible preparation (400 mg, n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All preparations (A, B, C)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Patients with CF-associated liver disease (n = 8)
Number of subjects: 29
Study: 1596385

Group type: EXPERIMENTAL
Intervention: Betadine and Tegaderm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betadine and gauze
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hibiclens and Tegaderm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hibiclens and gauze
Number of subjects: 60
Study: 6425911

Group type: EXPERIMENTAL
Intervention: Combined thioridazine (100 mg THI/day for the first 7 days) and desipramine (200 mg DMI/day for 21 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Desipramine (200 mg DMI/day for 21 days)
Number of subjects: 14
Study: 31847898

Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of five behavioural and organisational modules tailored to hospital employees.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group receiving the complex intervention after the last follow-up measurement.
Number of subjects: 0
Study: 30354838

Group type: EXPERIMENTAL
Intervention: Modified technique with a local mucosal flap (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional extracapsular tonsillectomy (n=50)
Number of subjects: 100
Study: 26832647

Group type: EXPERIMENTAL
Intervention: CareCentre
Number of subjects: 29
Study: 23978222

Group type: EXPERIMENTAL
Intervention: Midodrine (2.5 to 10 mg three times daily for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 20
Study: 22325733

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 6000 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19085624

Group type: COMPARATOR
Intervention: Single-dose maternal methadone administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Split-dose maternal methadone administration
Number of subjects: 40
Study: 17466338

Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (APO) 4 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15308893

Group type: EXPERIMENTAL
Intervention: Monolateral external fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early hip spica casting
Number of subjects: 0
Study: 11291581

Group type: EXPERIMENTAL
Intervention: Experimental treatments from the Health Education and Research Trial (HEART) Project
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing medical education strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organizational change strategies
Number of subjects: 0
Study: 9211569

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8390768

Group type: EXPERIMENTAL
Intervention: 600 mg of alpha lipoic acid daily for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 micrograms of selenium (sodium selenite) daily for 3 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1200 IE of D‐alpha‐tocopherol daily for 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no antioxidant treatment)
Number of subjects: 80
Study: 3105472

Group type: EXPERIMENTAL
Intervention: verapamil (5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: cromoglycate (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 15
Study: 30946382

Group type: EXPERIMENTAL
Intervention: CT‐EX group (extraluminal CT guided group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: CV‐IN group (conventional intraluminal intubation group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CT‐EX group
Number of subjects: 70

Group type: COMPARATOR
Intervention: CV‐IN group
Number of subjects: 70
Study: 27236818

Group type: EXPERIMENTAL
Intervention: VMI+ at 40 keV
Number of subjects: 47

Group type: COMPARATOR
Intervention: VMI at 70 keV
Number of subjects: 47

Group type: COMPARATOR
Intervention: F_0.5 series
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: VMI+ at 40, 50, and 60 keV
Number of subjects: 47
Study: 26601565

Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Number of subjects: 89
Study: 24338893

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy (Pravastatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 22816385

Group type: EXPERIMENTAL
Intervention: Okada Purifying Therapy (OPT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18795300

Group type: EXPERIMENTAL
Intervention: Radiography plus MRI
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Selective MRI
Number of subjects: 208

Group type: COMPARATOR
Intervention: Radiography only
Number of subjects: 208
Study: 17207146

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 60
Study: 15617591

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Activities of daily living and work status
Number of subjects: 50
Study: 12518489

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro
Number of subjects: 26

Group type: COMPARATOR
Intervention: Crest SpinBrush
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral-B Battery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Colgate Motion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral-B 3-D Excel
Number of subjects: 26

Group type: COMPARATOR
Intervention: Crest experimental toothbrush
Number of subjects: 26
Study: 10354193

Group type: EXPERIMENTAL
Intervention: Intensified lifestyle intervention for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment by cardiologists and general practitioners
Number of subjects: 60
Study: 7853578

Group type: EXPERIMENTAL
Intervention: 30 mg mitomycin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment (no maintenance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early instillations (for 6 or 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged treatment (either immediate or delayed)
Number of subjects: 0
Study: 1960560

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy (RT) to all initially involved nodal sites (total dose of 2,000 cGy, with an optional boost of 1,000 cGy)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Partial or no radiation therapy
Number of subjects: 222
Study: 6121683

Group type: EXPERIMENTAL
Intervention: Beta-blocker drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug treatment for mild hypertension
Number of subjects: 0
Study: 30921603

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation for 12 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group with regular resistance exercise
Number of subjects: 115
Study: 29188859

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cognitive performance (baseline tests)
Number of subjects: 52
Study: 26307564

Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning (RLP) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning enriched with Contraceptive Action Planning (RLP+) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information only control group
Number of subjects: 0
Study: 23684734

Group type: EXPERIMENTAL
Intervention: Physical disgust induction using audio scripts
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moral disgust induction using audio scripts
Number of subjects: 40
Study: 21479818

Group type: EXPERIMENTAL
Intervention: 4 L of clear liquids (group A; 92 patients)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: 90 mL of aqueous sodium phosphate (group B; 89 patients)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: 4 L of polyethylene glycol electrolyte solution (group C; 92 patients)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 291